Stock KNTPF KINTOR PHARMACEUTICAL LIMITED
Add to a list

Kintor Pharmaceutical Limited Share Price OTC Markets

Stocks

KNTPF

KYG5273B1077

Biotechnology & Medical Research

OTC Markets Traded
Market Closed -
OTC Markets
08:16:29 12/08/2026 pm IST 		5-day change 1st Jan Change
0.2399 USD +39.48% Intraday chart for Kintor Pharmaceutical Limited 0.00% +11.06%
19/08 Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
11/06 Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939 MT

Valuation: Kintor Pharmaceutical Limited

Market Cap 72Cr 11Cr 9.14Cr 8.58Cr 7.83Cr 15Cr 1.02TCr 15Cr 101.5Cr 39Cr 512.26Cr 40Cr 39Cr 1.7TCr P/E 2024
-2.53x
P/E 2025 -3.96x
Enterprise Value 77Cr 11Cr 9.83Cr 9.22Cr 8.42Cr 16Cr 1.09TCr 16Cr 109.13Cr 42Cr 550.81Cr 43Cr 42Cr 1.82TCr EV / Sales 2024
7,57,94,130x
EV / Sales 2025 2,82,45,180x
Free-Float
88.01%
Yield 2024 *
-
Yield 2025 -
* Estimated data More valuation ratios

Chart: Kintor Pharmaceutical Limited

Dynamic Chart

Latest news : Kintor Pharmaceutical Limited

19/08 Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
11/06 Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939 MT
10/06 Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material CI
28/05 Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares RE
27/05 Kintor Pharmaceutical Auditor to Retire; Shares Drop 7% MT
26/05 Kintor Pharmaceutical Limited Announces Change of Address of Principal Place of Business in Hong Kong, with Effect from 1 June 2026 CI
21/04 Kintor Pharmaceutical's 2026 Sales Jump Past 2025 Full-Year Level MT
20/04 Kintor Pharmaceutical says ytd 2026 sales revenue at RMB34 million RE
20/04 Kintor Pharmaceutical Limited Provides Sales Guidance for the Year 2026 CI
20/04 Kintor Pharmaceutical Limited Announces Preliminary Sales Results for the Year to Date Ended April 20, 2026 CI
30/03 Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
19/03 Kintor Pharma's Androgenetic Alopecia Drug Meets Primary Endpoint in Phase 3 Trial; Shares Plunge 21% MT
18/03 Kintor pharmaceutical says pharma's KX-826 phase III trial in China reaches primary endpoint RE
More news

Press Releases: Kintor Pharmaceutical Limited

28/23/28 Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine PU
11/23/11 Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China PU
28/23/28 Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights PU
22/23/22 Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China PU
20/23/20 Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA AQ
More press releases

Quotes and Performance

1 day+39.48%
Current month+39.48%
1 month+4.30%
3 months-25.48%
6 months-38.85%
Current year+11.06%
More quotes

Price Extremes

1 month 0.17
Extreme 0.172
 0.24
Current year 0.17
Extreme 0.172
 0.57
1 year 0.17
Extreme 0.172
 0.57
3 years 0.08
Extreme 0.0835
 0.57
5 years 0.08
Extreme 0.0835
 11.8
10 years 0.08
Extreme 0.0835
 11.8
More quotes

Managers and Directors: Kintor Pharmaceutical Limited

Manager TitleAgeSince
You Zhi Tong CEO
 Chief Executive Officer 64 24/03/2009
Ming Ming Cheung DFI
 Director of Finance/CFO 49 14/04/2023
Hong Long Lu CTO
 Chief Tech/Sci/R&D Officer 49 01/09/2020
Director TitleAgeSince
Yeung Wai Yim BRD
 Director/Board Member 62 12/08/2019
Min Xu BRD
 Director/Board Member 61 12/08/2019
You Zhi Tong CHM
 Chairman 64 24/03/2009
More insiders

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
KINTOR PHARMACEUTICAL LIMITED Stock Kintor Pharmaceutical Limited
+39.48%0.00% - - 11Cr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+3.31%-3.70%+61.03%+103.64% 7.14TCr
ARGENX SE Stock argenx SE
+2.09%+2.28%+49.95%+91.30% 6.42TCr
BIONTECH SE Stock BioNTech SE
-1.31%-0.50%+7.41%-4.29% 2.86TCr
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-3.21%-0.77%+55.10%+8.86% 2.73TCr
INSMED INCORPORATED Stock Insmed Incorporated
+0.40%-4.80%-5.89%+469.55% 2.71TCr
GENMAB A/S Stock Genmab A/S
-1.68%+0.33%+36.86%-16.09% 2.05TCr
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
+1.02%+6.43%+269.42%+420.34% 1.94TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Stock Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-0.29%-2.72%+11.89%+536.20% 1.6TCr
EXELIXIS, INC. Stock Exelixis, Inc.
-1.09%+3.14%+46.32%+155.12% 1.41TCr
Average +3.89%+4.06%+59.12%+196.07% 3.2TCr
Weighted average by Cap. +0.80%+3.29%+55.23%+154.73%
See all sector performances

Financials

2024 2025
Net sales 5 0.74 0.64 0.6 0.55 1.03 70.93 1.04 7.09 2.75 35.78 2.79 2.73 118.52 32.68 4.86 4.17 3.92 3.58 6.75 463.62 6.78 46.34 17.96 233.89 18.25 17.85 774.68
Net income -16Cr -2.31Cr -1.98Cr -1.86Cr -1.7Cr -3.21Cr -220.29Cr -3.22Cr -22Cr -8.53Cr -111.14Cr -8.67Cr -8.48Cr -368.1Cr -20Cr -2.98Cr -2.55Cr -2.4Cr -2.19Cr -4.13Cr -283.87Cr -4.15Cr -28Cr -11Cr -143.21Cr -11Cr -11Cr -474.33Cr
Net Debt -1.57Cr -23.32L -20.02L -18.79L -17.16L -32.38L -22Cr -32.54L -2.22Cr -86.16L -11Cr -87.56L -85.66L -37Cr 5.39Cr 80.11L 68.76L 64.54L 58.94L 1.11Cr 76Cr 1.12Cr 7.64Cr 2.96Cr 39Cr 3.01Cr 2.94Cr 127.67Cr
* Estimated data More financial data

Company Profile

Logo Kintor Pharmaceutical Limited
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.
Employees
123
Sector
Biotechnology & Medical Research
More about the company

Annual profits - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. 9939 Stock
  4. KNTPF Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong